Mystery Solved? GenSight’s Gene Therapy Does Move Between Eyes
Company hopes to file in Europe next year
Company boosted by animal study which helps answer riddle of improvement in untreated eye.
You may also be interested in...
French biotech GenSight Biologics reports top-line results from the Phase III REFLECT study, backing the efficacy of its lead gene therapy in a devastating eye disease, and prepares plans to commercialize the product.
Phase III success at 96 weeks sets up GenSight blindness therapy for EU filing, but puzzle of placebo arm benefits remain
Novavax has already gained its first emergency use authorization for its COVID-19 vaccine, but doubts remain about its manufacturing and Omicron readiness.